<DOC>
	<DOCNO>NCT02935686</DOCNO>
	<brief_summary>The primary purpose study assess safety/tolerability different vaccine regimens assess envelope ( Env ) -binding antibody ( Ab ) responses 2 different vaccine regimen .</brief_summary>
	<brief_title>A Safety , Tolerability Immunogenicity Study 2 Different Regimens Tetravalent Ad26.Mos4.HIV Prime Followed Boost With Tetravalent Ad26.Mos4.HIV Along With Either Clade C gp140 Plus Adjuvant OR With Combination Mosaic Clade C gp140 Plus Adjuvant Healthy HIV Uninfected Adults</brief_title>
	<detailed_description>This randomize ( study medication assign chance ) , double-blind ( neither physician participant know treatment receive ) , placebo-controlled ( placebo inactive substance compare drug test whether drug real effect clinical trial ) , parallel-group ( treatment group treat time ) , multicenter ( one clinical site ) study healthy human immunodeficiency virus ( HIV ) -uninfected adult . The study conduct 3 phase : 6-week screening period ; 48-week vaccination period ; follow-up period final visit Week 72 . The approximate duration study approximately 78 week . Participants safety monitor throughout study .</detailed_description>
	<mesh_term>Aluminum phosphate</mesh_term>
	<criteria>Participant must healthy basis medical history , physical examination , vital sign measurement perform screening Participants negative human immunodeficiency virus ( HIV ) infection screen Participants amenable HIVrisk reduction counsel commit maintain behavior consistent low risk HIV exposure last require protocol clinic visit All female participant childbearing potential must negative serum ( betahuman chorionic gonadotropin [ betahCG ] ) screen visit , negative urine pregnancy test predose Day 1 Participants willing/able adhere prohibition restriction specify protocol study procedure Has chronic hepatitis B ( measure hepatitis B surface antigen test ) active hepatitis C ( measure hepatitis C virus [ HCV ] Ab test ; positive , HCV ribonucleic acid [ RNA ] polymerase chain reaction ( PCR ) test use confirm active versus past HCV infection ) , active syphilis infection , chlamydia , gonorrhea , trichomonas In 12 month prior randomization , participant history newly acquire herpes simplex virus type 2 ( HSV2 ) , syphilis , gonorrhea , nongonococcal urethritis , chlamydia , pelvic inflammatory disease , trichomonas , mucopurulent cervicitis , epididymitis , proctitis , lymphogranulomavenereum , chancroid , hepatitis B Participant major surgery ( eg , require general anesthesia ) within 4 week screen , fully recover surgery , surgery plan course study Participant thyroidectomy active thyroid disease require medication last 12 month ( exclude : stable thyroid supplementation ) Current past drug/alcohol use investigator assess pose remotely increase risk ability participant comply protocol requirement Has receipt license vaccine within 14 day prior first dose study vaccine placebo , plan receive within 14 day first study vaccination , plan receive within 14 day second , third fourth vaccination Is recipient prophylactic therapeutic HIV vaccine candidate time , recipient experimental vaccine ( ) within last 12 month . For participant receive experimental vaccine ( except HIV vaccine ) 12 month ago , documentation identity experimental vaccine must provide sponsor , determine eligibility casebycase basis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>